1stOncology™: Cancer Intelligence Service – Page 8171 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Thermo Fisher Scientific Declares Quarterly Dividend

On July 8, 2021 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that its Board of Directors has authorized a quarterly cash dividend of $0.26 per common share, payable on October 15, 2021, to shareholders of record as of September 15, 2021 (Press release, Thermo Fisher Scientific, JUL 8, 2021, View Source [SID1234584758]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in July 2021

On July 8, 2021 Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, reported that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, is scheduled to participate in two upcoming virtual investor conferences in July 2021 (Press release, Beyond Air, JUL 8, 2021, View Source [SID1234584753]).

Details for Upcoming Conferences:

Event: Ladenburg Thalmann Annual Healthcare Conference 2021
Date and Time: July 13-14, 2021
Participation: Management will participate in a virtual fireside chat that is scheduled for Tuesday, July 13th at 3:30 PM ET, as well as 1-on-1 meetings virtually

Event: William Blair’s Biotech Focus Conference 2021
Date and Time: July 14-15, 2021
Participation: Management will be available for 1-on-1 meetings virtually

Please contact your representative at either Ladenburg Thalmann or William Blair to schedule a virtual one-on-one meeting with Beyond Air during the respective conference.

BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions

On July 8, 2021 BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, reported three new academic collaborations with MUSC Foundation for Research Development, Stanford University and the University of Pittsburgh (Pitt) to translate cutting-edge discoveries into potential therapies for patients with genetic diseases and genetically driven cancers (Press release, BridgeBio, JUL 8, 2021, View Source [SID1234584746]).

"The chance to partner with exceptional researchers at the Medical University of South Carolina, Stanford University and University of Pittsburgh is a privilege, and we believe will help us advance our mission to discover, create, test and deliver life-changing medicines for patients in need as rapidly as possible," said BridgeBio founder and CEO Neil Kumar, Ph.D.

To date, BridgeBio has worked with 23 leading institutions throughout the country that are focused on providing treatment options to patients as quickly and safely as possible. For a list of some of the institutions BridgeBio is partnered with, please visit Our Partners page.

iCo Therapeutics Inc. Announces TSX Venture Exchange Conditional Approval and Provides Update regarding Business Combination with Satellos Bioscience Inc.

On July 8, 2021 iCo Therapeutics Inc. ("iCo" or the "Company") (TSXV: iCo) (OTCQB: iCoTF) reported that the Company has received formal conditional approval from the TSX Venture Exchange (the "Exchange") of iCo’s proposed business combination (the "Transaction") with Satellos Bioscience Inc. ("Satellos") (Press release, iCo Therapeutics, JUL 8, 2021, View Source [SID1234584736]).

The Company has filed an information circular on SEDAR (the "Circular") that describes the Transaction in detail and will be mailing the Circular to shareholders on or about July 13, 2021. iCo has set August 3, 2021 as the date of the special meeting of shareholders of the Company to approve the Transaction, in accordance with the rules of the Exchange. The shareholder meeting is more fully described in the Circular.

In connection with the Transaction, iCo previously announced, on April 27, 2021, the successful closing of a private placement (the "Financing") of 85,294,117 subscription receipts (the "Subscription Receipts") at a price of $0.085 per Subscription Receipt for aggregate gross proceeds of approximately C$7.25 million, conditional upon successful closing of the Transaction. The Subscription Receipts will convert into common shares of iCo following the satisfaction of the escrow release conditions attached to the Subscription Receipts.

Finally, iCo announces that if the Transaction is approved by iCo and Satellos shareholders, the Company expects trading of the shares of the combined company to begin trading on the Exchange as Satellos Bioscience Inc. under the symbol MSCL during the week of August 9, 2021.

William Jarosz, the CEO of iCo noted, "We are grateful to the Exchange for their diligent work in approving this transaction. We are also grateful for the continuing support of iCo’s shareholders, both in participating in the Financing and for their patience during this time of change for the Company. We have a number of new strategic initiatives underway that involve the new assets and technology platform from Satellos and our older legacy assets. We believe we are beginning a new era for iCo and its shareholders."

Enveric Biosciences Announces Approval from Israel’s Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma

On July 8, 2021 Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, reported that the Company has received approval from the Israeli Ministry of Health to begin the Phase 1/2 portion of its study of its lead asset, EV101, designed to investigate the safety and efficacy of synthetic cannabidiol (CBD) when administered alone or in combination with clomiphene, concurrently with temozolomide, to treat patients suffering from recurrent or progressive glioblastoma (GBM) (Press release, Enveric Biosciences, JUL 8, 2021, View Source [SID1234584734]). The study will be conducted at the Davidoff Institute of Oncology, Rabin Medical Center, in Israel under Principal Investigator Dr. Tali Siegal.

"Glioblastoma is a highly aggressive form of cancer with a very poor overall survival rate, particularly for those with recurrent GBM, which is the target group for this study," said Robert Wilkins, M.D., Chief Medical Officer, Enveric Biosciences. "Our goal with this study is to enhance the existing treatment’s efficacy through adding CBD to create a new standard of care, potentially improving and extending glioblastoma patients’ quality of life."

The Phase 1 portion of the study is intended to first determine the CBD-temozolomide combination’s maximum tolerated dose (MTD). Clomiphene will then be added to the regimen for up to 24 patients to rule out toxicity. Once all three agents’ MTDs are determined, they will then be applied to the Phase 2 portion to determine initial efficacy, where an additional 40 patients are expected to be recruited and randomized into two open-label treatment arms.

The study design is as follows:

Arm 1 (combination): Patients will be treated with the MTD determined in the dose-finding phase for pure synthetic CBD oil + temozolomide.
Arm 2 (triple combination): Patients will be treated with the MTD determined in the dose-finding phase for pure synthetic CBD oil + temozolomide + clomiphene.
All patients will continue treatment for up to 24 months from Day 1 of the therapy unless unacceptable toxicities, patient consent withdrawal or death occur.
"We believe that the Israeli Ministry of Health’s approval for this Phase 1/2 study is a major milestone not only for Enveric but also for glioblastoma patients globally who are seeking to prolong their survival and improve their quality of life," added David Johnson, Chairman and CEO of Enveric Biosciences. "Our goal is to further demonstrate CBD’s efficacy when combined with current anti-cancer drugs to optimize the existing standard-of-care for cancer patients in need. We are targeting the fourth quarter of 2021 for the enrollment of our first patient, following the conclusion of the final study agreements with the site."

This product is not approved for marketing anywhere in the world.